These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37019896)

  • 1. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
    Bansal R; Baksh M; Larsen JT; Hathcock MA; Dingli D; Stewart AK; Kapoor P; Kourelis T; Hayman SR; Warsame RM; Fonseca R; Bergsagel PL; Ailawadhi S; Kumar SK; Lin Y
    Blood Cancer J; 2023 Apr; 13(1):47. PubMed ID: 37019896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation.
    Pasvolsky O; Pasyar S; Bassett RL; Khan HN; Tanner MR; Bashir Q; Srour S; Saini N; Lin P; Ramdial J; Nieto Y; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Cancer; 2024 May; 130(9):1663-1672. PubMed ID: 38127583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.
    Tschautscher MA; Jevremovic D; Rajkumar V; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Lin Y; Gonsalves WI; Kourelis T; Warsame R; Kyle RA; Kumar SK
    Am J Hematol; 2019 Jul; 94(7):751-756. PubMed ID: 30945330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Quantification of Minimal Residual Disease Pre- and Post-Unmanipulated Haploidentical Allograft by Multiparameter Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
    Wang XY; Fan QZ; Xu LP; Wang Y; Zhang XH; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Liu YR; Mo XD; Liu KY; Huang XJ; Chang YJ
    Cytometry B Clin Cytom; 2020 Jan; 98(1):75-87. PubMed ID: 31424628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation flow cytometry for MRD detection in patients with AL amyloidosis.
    Kastritis E; Kostopoulos IV; Theodorakakou F; Fotiou D; Gavriatopoulou M; Migkou M; Tselegkidi MI; Roussou M; Papathoma A; Eleutherakis-Papaioakovou E; Dialoupi I; Kanellias N; Ntalianis A; Rousakis P; Trougakos IP; Tsitsilonis O; Gakiopoulou C; Terpos E; Dimopoulos MA
    Amyloid; 2021 Mar; 28(1):19-23. PubMed ID: 32783569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel.
    Paiva B; Manrique I; Rytlewski J; Campbell T; Kazanecki CC; Martin N; Anderson LD; Berdeja JG; Lonial S; Raje NS; Lin Y; Moreau P; San-Miguel JF; Munshi NC; Kaiser SM
    Blood Cancer Discov; 2023 Sep; 4(5):365-373. PubMed ID: 37486974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
    Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
    Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
    Mohan M; Kendrick S; Szabo A; Yarlagadda N; Atwal D; Pandey Y; Roy A; Parikh R; Lopez J; Thanendrarajan S; Schinke C; Alapat D; Sawyer J; Tian E; Tricot G; van Rhee F; Zangari M
    Blood Adv; 2022 Feb; 6(3):808-817. PubMed ID: 34807986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
    Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
    Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood stem cell transplantation is an independent predictive parameter.
    Korthals M; Sehnke N; Kronenwett R; Bruns I; Mau J; Zohren F; Haas R; Kobbe G; Fenk R
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):423-431.e3. PubMed ID: 21745451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of lymphocyte patterns in multiple myeloma patients after autologous transplant.
    Stork M; Bezdekova R; Kralova R; Sandecka V; Adam Z; Krejci M; Boichuk I; Knechtova Z; Brozova L; Sevcikova S; Rihova L; Pour L
    Neoplasma; 2021 May; 68(3):519-527. PubMed ID: 33618517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
    Lahuerta JJ; Paiva B; Vidriales MB; Cordón L; Cedena MT; Puig N; Martinez-Lopez J; Rosiñol L; Gutierrez NC; Martín-Ramos ML; Oriol A; Teruel AI; Echeveste MA; de Paz R; de Arriba F; Hernandez MT; Palomera L; Martinez R; Martin A; Alegre A; De la Rubia J; Orfao A; Mateos MV; Blade J; San-Miguel JF;
    J Clin Oncol; 2017 Sep; 35(25):2900-2910. PubMed ID: 28498784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
    Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
    Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma.
    Chen W; Wang Y; Qi K; Shi M; Cao J; Bhansali R; Wang X; Liu Y; Li H; Zhang H; Yan Z; Sang W; Cheng H; Zhu F; Sun H; Li D; Jing G; Zheng J; Li Z; Xu K
    Transplant Cell Ther; 2021 Mar; 27(3):273.e1-273.e5. PubMed ID: 33781540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 19. MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma.
    Landgren O; Kazandjian D
    Blood Cancer Discov; 2023 Sep; 4(5):346-348. PubMed ID: 37655402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.
    Walter RB; Buckley SA; Pagel JM; Wood BL; Storer BE; Sandmaier BM; Fang M; Gyurkocza B; Delaney C; Radich JP; Estey EH; Appelbaum FR
    Blood; 2013 Sep; 122(10):1813-21. PubMed ID: 23847197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.